Inmunoterapia y Hemopatías 2024

Graduate and Doctorate in Medicine and Surgery from the UAB Consultant Assistant Doctor. Hospital del Mar. IMIM Associate Professor of the Faculty of Medicine UAB/UPF

JM Sancho completed his MD at the University of Navarra in 1992, and a residency in Haematology at the Germans Trias i Pujol Hospital in Barcelona. Dr Sancho focused his research in lymphoproliferative disorders, achieving a PhD from the Universitat Autonoma of Barcelona. He is specialist in Hematology-Hemotherapy, Germans Trias i Pujol University Hospital, Badalona. Dr.Sancho is coordinator of the Clinical Hematology Department of the Catalan Institute of Oncology (ICO) and works in the Deparment of Haematology at the Germans Trias I Pujol University Hospital in Badalona, Spain. Also, he is Principal Investigator at the Josep Carreras Leukaemia Research Institute in the grup of Lymphoid Neoplasms. He will contribute to the data base elaboration and will supervise clinical aspects of the project. He is author or co-author of articles and books’ chapters about lymphomas, ALL and stem cell transplantation. Dr. Sancho is the principal investigator in many phases I to IV clinical trials on lymphoproliferative disorders. He is member of the Spanish Society of Haematology (SEHH) and Spanish Lymphoma Group (GELTAMO).

Josep-Maria Ribera, prof, MD, PhD, is a reference figure in the field of acute lymphoblastic leukaemia (ALL).
• Among his most recent recognitions, he was elected as member of the Royal Academic of Medicine of Catalonia (Spain) in 2020, awarded with the Antonio Raichs Prize from the Spanish Society of Hematology (SEHH) in 2017 and with the Prize of Professional Excellence by the Medical College of Catalonia (Spain) in 2008. The SEHH awarded him for the best work on Hematology infectious pathology (1998) and for the best communication in two of their periodic Meetings (1993, 1997).
• Dr. Ribera has authored 1,189 publications indexed in the WoS (551 of them being original articles, reviews and letters), with 17.272 citations and an H-index of 64. He has also written 135 book chapters. He has been invited to participate as lecturer in 277 International Scientific Conferences and Meetings and has presented a total of 530 communications during his career. He has also chaired 55 sessions in international meetings.
• He coordinates and leads the ALL team of the Spanish Program of Hematology Treatments (PETHEMA) Group. He currently participates in two H2020- IMI2 projects (HARMONY, GA 116026, and HARMONY PLUS, GA 945406), of which he is the co-leader of the ALL workpackages.
• He contributed to two Consensus Documents of the Spanish Group of AIDS (GESIDA) on lymphomas (diagnosis and treatment) in HIV infected patients (2002). He is co-author of 2 Clinical Practice Guidelines of the European Society for Medical Oncology (ESMO), specifically on ALL in adult patients (2016), and ALL targeted therapy (in press, 2023), and co-author of the European Hematology Association (EHA) Roadmap for European Hematology Research (2016 & 2022). He has published two studies based on the results of the EHA Clinical Trial EPICOVIDEHA
(NCT04733729), on COVID-19 infections in patients with hematologic malignancies (2022 & 2023).
• Dr Ribera is evaluator of competitive grants for the Institute de Recherche du Cancer (France) and the Deutsche Krebshhilfe Priority Programme (Germany). He is evaluator for the SEHH, the Nacional Agency of Evaluation and Prospective (ANEP), the Spanish Association against Cancer (AECC), and the Health Research Fund (FIS).
• He is member of the Editorial Boards of Haematologica, Journal of Adolescent and Young Adult Oncology, World Journal of Hematology (WJH) and European Journal of Hematology. He is also executive secretary of the Journal Medicina Clinica. He is reviewer for 26 different journals, including New Engl J Med, Lancet, Lancet Oncology, Lancet Hematology, Blood, Journal of Clinical Oncology, Haematologica, British Journal of Hematology and American journal of hematology, among others.
• Dr Ribera holds prestigious roles in various international scientific societies: he is Board member of the EHA and the president of its Scientific Working Group (SWG) of ALL, he is founding member of the European Working Group on Adult ALL (EWALL) and also member of the Steering Committee of the European Leukemia Net (ELN). He is also member of American Society of Hematology (ASH) (reviewer of the Education Committee and coordinator of reviewers of abstracts), the Society of Hematology and Oncology (SOHO, member of the Education Committee) and the European Blood and Marrow Transplant (EBMT, member of the Acute Leukemia Working Party).
• He is full Professor of Medicine at the Universitat Autònoma de Barcelona and ViceDean of students’ international exchange. He has supervised 20 PhD students and directed 6 doctoral theses.
• He holds a high-level decision-making position as Head of the Clinical Hematology Service of the Catalan Institute of Oncology at Germans Trias i Pujol Hospital since 2003, and Clinical Director of the Josep Carreras Leukaemia Research Institute (IJC) since 2019

MD, PhD
Director of the CAR-T Program, Hospital Vall Hebron, Barcelona
Associate Professor at Autonomous University of Barcelona and Vic University, Barcelona, Spain
Pere Barba is the Clinical lead of Advanced Therapies in the Hematology Department of the Vall Hebron University Hospital. He serves as Associate Professor at the Autonomous University of Barcelona and Vic-UCC University.
He achieved his medical degree and did his Fellowship in Hematology at Hospital Sant Pau in Barcelona. He completed his training at Hôpital Saint Louis in Paris, France and served as Visiting Investigator at the Bone Marrow Transplantation Service at Memorial Sloan Kettering Cancer Center in New York. He obtained his clinical PhD in 2014 by the Autonomous University of Barcelona.
Dr Barba is the Coordinator Elect of the Spanish CAR T-cell working party of the GETH Group, an active member of the acute lymphoblastic leukaemia (ALL)-Spanish PETHEMA Group and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) and participates in several Joint Accreditation Committee ISCT-Europe (JACIE) initiatives regarding immune effector cells.
Dr. Barba has focused his main interests on CAR-T cells, immunotherapy, ALL, allogeneic cells, and transplantation, publishing more than 100 articles in peer reviewed journals and book chapters on these areas. He is a member of the Spanish acute lymphoblastic leukaemia Group (PETHEMA) and the ALL-Working Party of the EBMT, participating also in several initiatives of the Joint Accreditation Committee ISCT-Europe